New immune drug FL115 takes on Hard-to-Treat cancers

NCT ID NCT07131189

Ongoing Disease control Sponsor: Suzhou Forlong Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests FL115, a protein designed to boost the body's immune cells to fight cancer. It involves 30 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FL115 (a lab-made protein that boosts immune cells to fight cancer)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so the drug may not be effective or could cause unexpected side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED / METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm metastatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED / METASTATIC SOLID TUMORS

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Shandong Cancer Hospital

Jinan, Shandong, 250117, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.